Biomea Fusion Reaches Enrollment Milestone in Key Phase II Diabetes Trial—What the COVALENT-211 Update Means for Insulin-Deficient T2D Patients
Market Chameleon (Tue, 25-Aug 11:08 AM)
Biomea Fusion Hits Enrollment Milestone for Icovamenib Phase II Trial in Insulin-Deficient Type 2 Diabetes
Market Chameleon (Mon, 24-Aug 10:30 AM)
